PGEN — Precigen, Inc.

Summary of Precigen's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Precigen reported total revenues of $55 million for Q2 2026, with $53.1 million attributed to PAPZIMEOS, marking a 145% increase from $21.6 million in Q1.
• Profitability: The company achieved a net profit of $20.1 million, or $0.05 per diluted share, for the quarter, a significant milestone prior to the first anniversary of PAPZIMEOS approval.
• Gross Margin: The gross margin for PAPZIMEOS was reported at 95%, expected to stabilize between the high 80s and low 90s as pre-approval inventory is consumed.
• Expenses: R&D costs decreased to $7.3 million, while SG&A expenses rose to $22.2 million due to increased commercial activities.
• Cash Position: The company ended the quarter with $38.7 million in cash and equivalents, with a forecast to reach cash flow breakeven by the end of 2026.

2. Strategic Updates and Business Highlights

• PAPZIMEOS Launch: The product continues to gain traction as the first-line standard of care for adults with recurrent respiratory papillomatosis (RRP). The FDA granted PAPZIMEOS 7-year market exclusivity, enhancing its competitive position.
• Patient Engagement: Over 500 patients are registered in the Precigen Hub, with significant patient identification occurring outside the hub as well. The company noted broadening access and increasing physician adoption.
• Durability Data: Long-term follow-up data indicates that 83% of patients remain surgery-free beyond three years after treatment.
• Regulatory Progress: PAPZIMEOS is under review by the EMA, and a pediatric clinical trial is set to begin this year.

3. Forward Guidance and Outlook

• Growth Expectations: The company anticipates continued revenue growth into Q3, supported by strong demand indicators, payer coverage, and account activation.
• Market Potential: Precigen believes that the RRP indication has blockbuster potential, with a significant number of patients still to be treated.
• Pipeline Development: The company is advancing its pipeline, particularly PRGN-2009, which targets HPV-related cancers.

4. Bad News, Challenges, or Points of Concern

• Sustainability of Growth: While Q2 showed exceptional growth, there is a recognition that growth rates may diminish over time as the product matures in the market.
• Cost of Goods Sold (COGS): Future gross margins may decline as the company transitions from pre-approval inventory, with steady-state COGS expected to be around 10%.
• Market Competition: The company faces potential competition as it continues to expand its market presence, although the exclusivity granted by the FDA mitigates some risks.

5. Notable Q&A Insights

• Growth Trajectory: Management indicated that while growth rates may taper, they expect continued demand driven by strong commercial fundamentals and the recent introduction of a permanent J-code for reimbursement.
• Patient Onboarding: There is a healthy mix of patients being treated both through the Precigen Hub and external institutions, with significant contributions from both.
• Pent-Up Demand: There are several thousand patients in the severe category who could potentially drive revenue, but the company has not fully tapped into this segment yet.
• Impact of J-Code: The permanent J-code has positively influenced patient onboarding and treatment, with institutions previously hesitant to adopt now beginning to engage.

Overall, Precigen's Q2 2026 results reflect strong commercial momentum for PAPZIMEOS, with promising financial performance and strategic initiatives aimed at sustaining growth and expanding market access. However, the company remains cautious about the sustainability of growth rates and the potential impact of competition.